BL Pharmtech Corp. Logo

BL Pharmtech Corp.

Manufactures and distributes health foods, supplements, and cosmetics with bio-pharmaceutical R&D.

065170 | KO

Overview

Corporate Details

ISIN(s):
KR7065170003
LEI:
Country:
South Korea
Address:
경기도 용인시 수지구 신수로 767 134호(동천동, 분당수지유타워 지식산업센터), 용인시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BL Pharmtech Corp., formerly Next BT Co Ltd, is a company engaged in the health food and biotechnology sectors. Established in 1995, its primary business involves the manufacturing, distribution, import, and export of health functional foods, dietary supplements, and cosmetics. The company is also active in bio-pharmaceutical research and development, collaborating with academic institutions such as KAIST and Columbia University Medical Center through its subsidiaries, BL Melanies and BL Science. These research efforts are centered at the Daedeok Research Complex.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-07-30 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제21회차 CB)
Korean 5.6 KB
2025-07-28 00:00
Regulatory News Service
[기재정정]단일판매ㆍ공급계약체결
Korean 12.8 KB
2025-07-22 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 56.8 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.2 MB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 17.5 KB
2025-03-28 00:00
Share Issue/Capital Change
전환가액의조정 (제19회차)
Korean 13.1 KB
2025-03-21 00:00
Audit Report / Information
감사보고서제출
Korean 26.6 KB
2025-03-21 00:00
Annual Report
사업보고서 (2024.12)
Korean 2.0 MB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 6.6 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 187.3 KB
2025-03-12 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 9.6 KB
2025-02-27 00:00
Share Issue/Capital Change
전환가액의조정
Korean 21.1 KB
2025-02-27 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 103.9 KB
2025-02-27 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB

Automate Your Workflow. Get a real-time feed of all BL Pharmtech Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BL Pharmtech Corp.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BL Pharmtech Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Chemomab Therapeutics Ltd. Logo
Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.
United States of America
CMMB
CHINA PHARMA HOLDINGS, INC. Logo
Develops, manufactures, and sells prescription, OTC, and nutritional products for human use.
United States of America
CPHI
China SXT Pharmaceuticals, Inc. Logo
Researches, produces, and sells advanced Traditional Chinese Medicine (TCM) herbal products.
United States of America
SXTC
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea
034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan
4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden
CINPHA
Cingulate Inc. Logo
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America
CING
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway
CRNA
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America
CTOR
Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America
CTXR

Talk to a Data Expert

Have a question? We'll get back to you promptly.